Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Binding constructs and methods for use thereof

A technology combining structural domains and populations, applied in chemical instruments and methods, antibodies, drug combinations, etc., can solve problems such as short action time

Inactive Publication Date: 2012-08-22
EMERGENT PRODUCTS DEVELOPMENT SEATTLE LLC
View PDF86 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Plasmapheresis to reduce autoantibody levels in the blood is effective in MG but is short-lived because autoantibodies continue to be produced

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Binding constructs and methods for use thereof
  • Binding constructs and methods for use thereof
  • Binding constructs and methods for use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0551] Cloning of 2H7 variable region and construction and sequencing of 2H7 scFv-Ig

[0552] This example illustrates the cloning of cDNA molecules encoding the heavy and light chain variable regions of monoclonal antibody 2H7. This example also demonstrates the construction, sequencing and expression of 2H7 scFv-Ig.

[0553] Cells expressing the 2H7 monoclonal antibody that specifically binds CD20 were grown in logarithmic phase for several days in RPMI 1640 medium (Invitrogen / Life Technologies, Gaithersburg, MD) supplemented with gluten before harvesting. Aminoamide, pyruvate, DMEM non-essential amino acids, and penicillin-streptomycin. Pellet the cells from the culture medium by centrifugation and use 2x10 7 Cells make RNA. RNA was isolated from 2H7-producing hybridoma cells using the Pharmingen (San Diego, CA) Total RNA Isolation Kit (Cat# 45520K) according to the manufacturer's instructions accompanying the kit. cDNA was prepared by reverse transcription using 1 micr...

Embodiment 2

[0559] Expression of 2H7scFv-Ig in Stable CHO Cell Line

[0560] This example illustrates the expression of 2H7scFv-Ig in eukaryotic cell lines and the characterization of expressed 2H7scFv-Ig by SDS-PAGE and functional assays including ADCC and complement fixation.

[0561]The 2H7scFv-Ig HindIII-XbaI (about 1.6kb) fragment with the correct sequence was inserted into the mammalian expression vector pD18, and the DNA of the positive clone was amplified with the QIAGEN plasmid preparation kit (QIAGEN, Valencia, CA). Recombinant plasmid DNA (100 μg) was then linearized in non-essential regions by digestion with AscI, purified by phenol extraction, and resuspended in tissue culture medium Excell 302 (Cat# 14312-79P, JRH Biosciences, Lenexa, KS) middle. The cells used for transfection, CHO DG44 cells, were kept in logarithmic growth, and 10 cells were harvested for each transfection reaction. 7 cells. Linearized DNA was added to CHO cells in a total volume of 0.8 ml for electrop...

Embodiment 3

[0570] Effects of simultaneous ligation of CD20 and CD40 on normal B cell growth, CD95 expression and induction of apoptosis

[0571] This example illustrates the effect of cross-linking of CD20 and CD40 expressed on the cell surface on cell proliferation.

[0572] Dense quiescent B cells were isolated from human tonsils by a Percoll graded gradient and T cells were depleted by E-rosetting. During the last 12 hours of the 4-day experiment, by 3 The uptake of [H]-thymidine, the proliferation of quiescent, densely packed tonsillar B cells was measured. Proliferation was measured in quadruplicate cultures with means and standard deviations as indicated. Mouse anti-human CD20 mAb 1F5 (anti-CD20) alone or cross-linked with anti-mouse kappa mAb 187.1 (anti-CD20XL) was used. CD40 activation was accomplished using soluble human CD154 fused to murine CD8 (CD154) (Hollenbaugh et al., EMBO J 11:4212-21 (1992)) and anti-mouse CD8 monoclonal antibody 53-6 (CD154XL) CD40 cross-linking i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgGI hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and / or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

Description

[0001] This application is a divisional application of an invention patent application titled "Binding Constructs and Methods of Use" of the international application PCT / US 2003 / 041600 entered into China with an international filing date of December 24, 2003, and application number 200380110470.3. [0002] All applications from which this application claims priority are hereby incorporated by reference in their entirety. technical field [0003] The present invention relates generally to compounds that have a variety of applications, including use in research, diagnosis, and therapy (eg, immunotherapy). Compounds of the invention include immunologically active proteins and protein conjugates. Such proteins include recombinant or engineered binding proteins, eg, binding domain-immunoglobulin fusion proteins, which may include single chain Fv-immunoglobulin fusion proteins and compounds containing single chain Fv-immunoglobulin. The present invention also relates to compositio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/46A61K39/395A61P35/00A61P35/02A61P29/00A61P19/02A61P21/04A61P3/10A61P25/00A61P37/00C07K16/28
CPCA61K2039/505C07K16/2809C07K16/2818C07K16/2878C07K16/2896C07K16/462C07K16/464C07K2317/22C07K2317/24C07K2317/53C07K2317/56C07K2317/622C07K2317/64C07K2317/732C07K2317/734C07K2319/00C07K2319/30A61P1/04A61P17/06A61P19/02A61P21/04A61P25/00A61P29/00A61P35/00A61P35/02A61P37/00A61P43/00A61P7/04A61P3/10C07K2/00C07K16/00
Inventor J·A·莱德贝特M·S·海登-莱德贝特P·A·汤普逊
Owner EMERGENT PRODUCTS DEVELOPMENT SEATTLE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com